The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4645-4653

  Wilson, James W ^a   Potten, Christopher S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL CYCLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

16,16-DIMETHYLPROSTAGLANDIN E2; ANIMALS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DUODENAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; ILEAL NEOPLASMS; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MITOSIS; THYMIDINE;

EID: 0034662652     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
2. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
3. Min: A mouse model for intestinal and mammary tumorigenesis
4. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by nonsteroidal anti-inflammatory agent indomethacin
5. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
6. Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
7. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC (min)/+ mouse model: Implications for prophylaxis and treatment of colon cancer
8. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
9. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis
10. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent
11. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
12. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane-induced colonic tumours in rats
13. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the post-initiation stage of colon carcinogenesis
14. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours
15. 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone
16. Elevated cyclooxygenase-2 levels in Min mouse adenomas
17. Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A
18. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2
19. In vivo analysis of cadherin function in the mouse intestinal epithelium: Essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death
20. Cyclooxygenase-2 expression inhuman colon cancer cells increases metastatic potential
21. Δ176 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
22. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
23. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
24. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice
25. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice
26. 2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats
27. Altered eicosanoid levels in human colon cancer
28. 2
29. 2 prostaglandins modulate cell proliferation in the small intestinal epithelium of the rat
30. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo
31. 2 in human colon cancer cells
32. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
33. WAF-1/CIP1 expression in the murine intestinal epithelium: Apoptosis and ceLl cycle arrest
34. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1
35. Administration of an unconjugated bile acid increases duodenal tumours in a murine model of familial adenomatous polyposis
36. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: An in vitro study
37. Antiproliferative effects of the enantiomers of fluribprofen
38. Sulindac inhibits colorectal tumour growth but not prostaglandin synthesis in the rat
39. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
40. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer
41. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
42. Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines
43. 2 biosynthesis in cyclooxygenase 1 or 2 null cells
44. What is an apoptotic index measuring? A commentary
45. Stem cells in the gastrointestinal epithelium: Numbers, characteristics and death
46. Waf1, a potential mediator of p53 tumour suppression
47. 1 cyclin-dependent kinases
48. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
49. Effects of antisense p21(WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukaemic cells (HL-60)
50. WAF-1/CIP1 during differentiation
51. sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts
52. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
53. 2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine
54. Distribution of prostaglandin E receptors in the rat gastrointestinal tract
55. Metabolism of prostaglandin E analogues in the guinea pig liver mitochondrial fraction
56. 2 in the human female
57. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
58. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
59. 15-deoxy-Δ-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ
60. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
61. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumours in C57BL/6J-APCMin/+ mice
62. 15-deoxy-Δ(12, 14)-prostaglandin J2, a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells
63. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12, 14-prostaglandin J2
64. Regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs